Liver transplant depends on access to necessary medication

In a clinical trial involving 62 cholangiocarcinoma patients, Ziihera showed a 52% response rate, with effects lasting a median of 15 months, indicating its potential as a second-line therapy for HER2-targeted cancers. However, Cigna’s denial for patient Middleton’s coverage cited a requirement for prior HER2 therapy, despite evidence suggesting Ziihera’s efficacy without it, raising concerns among doctors about its use.

Want More Context? 🔎